Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00009841 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy in Treating Patients With Advanced Head and Neck Cancer
A Phase 1 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00009841 is a Phase 1 study that has completed, run by University of Pittsburgh. The registered enrollment target is 13 participants.
The verdict
NCT00009841, a Phase 1 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
RATIONALE: Gene therapy may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have advanced head and neck cancer.
Interventions
- BIOLOGICAL EGFR antisense DNA
- BIOLOGICAL growth factor antagonist therapy
- DRUG DC-cholesterol liposome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 1999-03 |
| Est. Completion | 2002-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00009841
The ClinicalTrials.gov registry entry for NCT00009841 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which EGFR antisense DNA is the first listed.
NCT00009841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00009841 about?
NCT00009841 is a clinical study titled "Gene Therapy in Treating Patients With Advanced Head and Neck Cancer". RATIONALE: Gene therapy may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have advanced head and neck cancer.
What is the current status of trial NCT00009841?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 1999-03. Estimated completion is 2002-03.
What interventions are being tested in trial NCT00009841?
The interventions under investigation include: EGFR antisense DNA (BIOLOGICAL), growth factor antagonist therapy (BIOLOGICAL), DC-cholesterol liposome (DRUG).
Who is sponsoring clinical trial NCT00009841?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.